STERIS and Scantago Distribution Agreement July 2011
MENTOR, OH - July 22, 2011 - STERIS is pleased to confirm that Scantago ApS of Holbæk (www.scantago.com) has been appointed official distributor for STERIS Life Science Formulated Chemistries products and will serve the territory of Denmark.
Within the product ranges for which Scantago will assume responsibility are cleaning agents, antimicrobial formulations and sterility assurance products (biological and chemical indicators). These products are manufactured to the highest standards (ISO 9001, ISO 13485) in FDA inspected facilities operating to cGMP standards. All products are supported with a wide range of highly detailed technical literature to aid their fast, easy adoption and validation within the research and manufacturing environments of the Pharmaceutical and Biopharmaceutical markets. STERIS manufacturing facilities and quality systems are open to Customer audit and inspection upon request.
Andy Todd, European Sales Manager, STERIS commented we are delighted with Scantago's appointment, which has followed a couple of years of proactive support for the STERIS product ranges in an unofficial capacity. During that time, we have worked closely with Scantago and have been highly impressed with their experience and level of understanding of the applications for the STERIS products. Every Pharma and Biopharma Customer, regardless of size, will benefit from this knowledge and coupled with STERIS quality products and hugely important support package, we believe a winning formula has been created for the Danish market.
Tony Christensen, owner of Scantago has always considered STERIS brand and STERIS products as very interesting and valuable. From a Scantago perspective we were given the opportunity to collaborate with STERIS on the consumable business, this opportunity is a very strong complement to our core business. Tony Christensen commented we meet many Customers in the Pharma and Biopharma industry who appreciate the benefits of STERIS consumables in their production and research activities. Scantago looks forward to be a part of the value chain supplying STERIS consumables to the Danish Customers in the future."
About STERIS Corporation
STERIS Corporation is a leading provider of infection prevention and surgical products and services, focused primarily on critical healthcare, pharmaceutical and research markets. The Company's approximately 5,000 dedicated employees around the world work together to supply a broad array of equipment, consumables and services solutions that enhance Customer productivity and quality and help make the world a safer place. The Company is listed on the New York Stock Exchange under the symbol STE. For more information, visit www.steris.com.
For more information about this and other STERIS research technologies, please visit www.sterislifesciences.com.
This news release may contain statements concerning certain expectations, forecasts, estimates, product performance or other forward-looking information affecting or relating to the Company or its products that are intended to qualify for the protections afforded "forward- looking statements" under the Private Securities Litigation Reform Act of 1995 and other laws and regulations. Forward-looking statements speak only as to the date of this report, and may be identified by the use of forward-looking terms such as "may," "will," "expects," "believes," "anticipates," "plans," “new,” “advanced,” and “best available,” or the negative of such terms or other variations on such terms or comparable terminology. Many important factors could cause actual results to differ materially from those in this news release including, without limitation, disruption of production or supplies, changes in product use, pending or future claims, technology advances, and changes in government regulations or the application or interpretation thereof. No assurances can be provided as to any product performance or product safety unless all labeling, instructions for use, MSDS and other product literature are strictly followed. Unless legally required, the Company does not undertake to update or revise any forward-looking statements even if events make clear that any projected results, express or implied, will not be realized. Other potential risks and uncertainties that could cause actual results to differ materially from those in this news release include, without limitation, (a) the possibility that market demand will not develop for new technologies, products or application; (b) the possibility that application of or compliance with laws, court rulings, regulations, certifications or other requirements or standards may delay or prevent product introductions, affect the production and marketing of existing products, or otherwise affect product performance; or (c)uses not consistent with product instructions. Product descriptions and performances herein are for illustration only and do not modify labeling, warranties or other technical literature.